Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palliative pharmacotherapy for cancer-related fatigue
IRCT20150302021307N6Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylphenidate, bupropion, ginseng and amantadine in cancer-related fatigue (CRF) (5 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoint: Fatigue level. Started Sep 2023; status: completed.
02
Drugs
methylphenidatebupropionginsengamantadine
03
Conditions
cancer-related fatigue (CRF)
Beyond the preview
Go deeper on IRCT20150302021307N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150302021307N6.